Pharmaceuticals

LIVZON PHARMA

Lizhu Pharmaceutical Announces Q1 2026 Financial Report

LIVZON PHARMA released FY2026 Q1 earnings on April 23 Pre-Market (BJT), actual revenue HKD 3.255 B (forecast HKD 3.596 B), actual EPS HKD 0.7369 (forecast HKD 0.816)

LIVZON PHARMA to Release FY2026 Q1 Earnings on April 23 Pre-Market (BJT), Forecast Revenue HKD 3.595 B, EPS HKD 0.816

Lizhu Pharmaceutical Subsidiary Granted Clinical Trial Approval for Injectable Brexpiprazole Microsphere

LIVZON PHARMA released FY2025 Q4 earnings on March 24 After-Market (BJT), actual revenue HKD 3.23 B (forecast HKD 3.129 B), actual EPS HKD 0.3399 (forecast HKD 0.4164)

LIVZON PHARMA released FY2025 earnings on March 24 After-Market BJT, actual revenue HKD 13.14 B (forecast HKD 13.54 B), actual EPS HKD 2.476 (forecast HKD 2.5931)

LIVZON PHARMA to release FY2025 earnings on March 24, pre-market BJT, forecast revenue HKD 13.7 B, EPS HKD 2.5931

Lizhu Group's Subsidiary and Beijing XinKanghe Jointly Developed Lekangqita Monoclonal Antibody Injection Included in Priority Review List

Lizhu Pharmaceutical Extends Equity Transfer Deadline for Acquisition of Vietnamese Listed Company Imexpharm Corporation to June 30, 2026

Lizhu Pharmaceutical Plans Public Tender Offer to Acquire Shares of Imexpharm Corporation

Lizhu Pharmaceutical and XinKangHe BioMed's Lekangqita Injection Receives NMPA Marketing Authorization Application Acceptance

Lizhu Pharmaceutical Factory Obtains Approval for NS-041 Tablet's New Clinical Trial for Depression

Lizhu Pharmaceutical Donates 10 Million HKD to Support Victims of Hong Kong Fire

Lizhu Pharmaceutical repurchased 160,100 A-shares

Lizhu Pharmaceutical Repurchased 164,000 A-shares for 5.9969 Million Yuan

2025 National Medical Insurance Catalog Negotiation Launched

LIVZON PHARMA released FY2025 Q3 earnings on October 23 Pre-Market (BJT), actual revenue HKD 3.109 B (forecast HKD 3.084 B), actual EPS HKD 0.5788 (forecast HKD 0.6559)

LIVZON PHARMA released FY2025 9 Months earnings on October 23 Pre-Market (BJT), actual revenue HKD 9.899 B, actual EPS HKD 2.127

LIVZON PHARMA to Release FY2025 Q3 Earnings on October 23 Pre-Market (BJT), Forecast Revenue HKD 3.072 B, EPS HKD 0.6531

Lizhu Group's Secretary Responds to Investor Questions

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

Ordinary dividend (cash)

Ex Date: 2026.06.16, Cash dividend 1.6247 HKD

01513

159506

510660

513700

520690

562050

512010

512290

Livzon Pharmaceutical Group has completed a voluntary public tender offer for shares in Vietnam’s Imexpharm Corporation, acquiring a controlling stake of 67.87% of Imexpharm’s registered capital. The offer period closed on April 29, 2026, with shareholders tendering 104,545,781 shares at VND57,400 each. This acquisition strengthens Livzon's position in Vietnam's pharmaceutical market as part of its regional expansion strategy. The latest analyst rating for Livzon's stock (HK:1513) is a Sell, with a price target of HK$22.99.

Tip Ranks

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

LIVZON GROUP

Livzon Secures Controlling Stake in Vietnam’s Imexpharm After Tender Offer Completion

Livzon Pharmaceutical Group has issued a revised proxy form for its 2025 AGM, scheduled for May 29, 2026, correcting typographical and formatting issues. The original form is now void, and shareholders must resubmit the revised form. The company apologized for any inconvenience. The latest analyst rating for Livzon's stock (HK:1513) is a Sell, with a price target of HK$22.99. Livzon is a Hong Kong-listed pharmaceutical company involved in the research, production, and sale of medicines.

Livzon Pharmaceutical Issues Revised Proxy Form for 2025 AGM

Livzon Pharmaceutical Group has scheduled its 2025 annual general meeting for May 29, 2026, in Zhuhai, allowing both on-site and online voting. The agenda includes approval of the annual report, reappointment of Grant Thornton as auditor, and a cash dividend plan of RMB14.3 per 10 shares. The company emphasizes its commitment to returning cash to investors. The latest analyst rating for Livzon Pharmaceutical (HK:1513) is a Sell, with a price target of HK$22.99.

Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend Plan

000513

Livzon Pharmaceutical Group reported a decline in first-quarter 2026 results, with operating income of RMB2.871 billion and net profit of RMB577 million, down 9.73% and 9.39% year-on-year, respectively. The decrease is attributed to industry policy adjustments and seasonal demand fluctuations. However, net cash flow from operating activities increased by 12.8% to RMB817 million, and shareholders’ equity rose by 4.47%. The company maintains a stable balance sheet with total assets at RMB24.19 billion. Analysts currently rate the stock as a Sell with a price target of HK$22.99.

Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue

159570

513120

In a report released on April 13, from CICC maintained a Buy rating on Livzon Pharmaceutical Group, with a price target of HK$39.00. The company’s shares closed last Thursday at HK$28.24.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Hold analyst consensus rating for Livzon Pharmaceutical Group with a HK$31.01 average price target.

China Universal CNI HK Connect Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

CICC

CR MEDICAL

CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)

159316

588130

LIVZON PHARMA announced that its application for JP-1366 tablets has been approved by the National Medical Products Administration to conduct clinical trials in combination with antibiotics to eradicate Helicobacter pylori. JP-1366 tablets are an innovative potassium ion competitive acid blocker, which had previously been applied for the treatment of gastroesophageal reflux disease and was accepted in August 2025; the injectable form for the Phase II clinical trial for bleeding peptic ulcers began in October 2025

AASTOCKS

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

LIVZON PHARMA JP-1366 tablets for the eradication of Helicobacter pylori clinical trial approved

Livzon Pharmaceutical Schedules Board Meeting to Review First-Quarter 2026 Results

Livzon Pharmaceutical Schedules Board Meeting to Review First-Quarter 2026 Results

512170

LIVZON PHARMA announced its 2025 annual performance, achieving operating revenue of 12.02 billion RMB (same below), an increase of 1.8% year-on-year. The net profit attributable to shareholders was 2.023 billion RMB, a decline of 1.8%, with earnings per share of 2.24 RMB. A dividend of 14.3 RMB per 10 shares was declared

Hwabao WP CSI Medical Service ETF

"Performance" LIVZON PHARMA's annual net profit is RMB 2.023 billion, down 1.8%, with a dividend of RMB 14.3 per 10 shares

Livzon Pharmaceutical Outlines Board and Committee Structure

Livzon Pharmaceutical Outlines Board and Committee Structure

LIVZON PHARMA(01513.HK)

Livzon Secures Controlling Stake in Vietnam’s Imexpharm After Tender Offer Completion

Livzon Pharmaceutical Issues Revised Proxy Form for 2025 AGM

Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend Plan

Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue

CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)

LIVZON PHARMA JP-1366 tablets for the eradication of Helicobacter pylori clinical trial approved

Livzon Pharmaceutical Schedules Board Meeting to Review First-Quarter 2026 Results

"Performance" LIVZON PHARMA's annual net profit is RMB 2.023 billion, down 1.8%, with a dividend of RMB 14.3 per 10 shares

Livzon Pharmaceutical Outlines Board and Committee Structure

Trending